
Scholar Rock Holding Corp
96
Recent developments highlight FDA approval and U.S. launch of ISEMBYLD, regulatory filings in Europe and Japan, and ongoing clinical trial progress for pipeline candidates.
- Scholar Rock received FDA approval for ISEMBYLD in September 2026 and commenced U.S. commercial launch in Q3 2026 [N1][S2].
- The company resubmitted its Marketing Authorisation Application for apitegromab to the European Medicines Agency in October 2026 [N1].
- Scholar Rock submitted a Japanese New Drug Application for apitegromab in November 2026 [S2].
- Ongoing clinical trials include the long-term extension ONYX study and Phase 2 OPAL trial for SMA patients under two years, and Phase 2 FORGE trial for FSHD initiated in Q2 2026 [S2][N3][N4].
- A Phase 1 study of a subcutaneous formulation of apitegromab has completed with favorable results; further regulatory engagements are planned [S2].
- The investigational antibody SRK-439 is in Phase 1 clinical trial with topline data expected by year-end 2026 [S2].
- Scholar Rock reported $0.57 million in net product revenue from ISEMBYLD sales in Q3 2026, its first quarter of commercial sales [S2].
- Research and development expenses increased 7.2% year-over-year to $54.1 million in Q3 2026, reflecting ongoing development activities [S2].
- The company maintains strong liquidity with $366.3 million in cash and equivalents and a current ratio of 5.41 as of September 30, 2026 [S2].
Scholar Rock Holding Corp operates as a global biopharmaceutical company specializing in rare neuromuscular diseases, primarily spinal muscular atrophy (SMA). The company’s proprietary technology platform enables the discovery and development of monoclonal antibodies that selectively inhibit latent forms of growth factors in the transforming growth factor beta (TGFβ) superfamily. Scholar Rock’s lead product, ISEMBYLD™ (apitegromab-mstn), is the first muscle-targeted therapy approved by the FDA for SMA patients receiving SMN2-targeted treatment. The company has initiated commercial sales of ISEMBYLD in the U.S. and is pursuing regulatory approvals in Europe and Japan. Its clinical pipeline includes ongoing trials for SMA in younger patients, facioscapulohumeral muscular dystrophy (FSHD), and development of a subcutaneous formulation of apitegromab. Additional pipeline candidates target other rare diseases and oncology indications. Scholar Rock has incurred significant operating losses historically and maintains a strong cash position to support ongoing development and commercialization activities.
Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapies for spinal muscular atrophy (SMA) and other rare neuromuscular diseases. The company’s proprietary platform targets the transforming growth factor beta (TGFβ) superfamily to develop monoclonal antibodies that inhibit growth factor activation. Its lead product, ISEMBYLD™ (apitegromab-mstn), received FDA approval in September 2026 for SMA treatment and commenced U.S. commercial launch in Q3 2026. The company reported $0.57 million in product revenue for the quarter ended September 30, 2026, alongside a net loss of $107.2 million and research and development expenses of $54.1 million. Scholar Rock maintains strong liquidity with over $366 million in cash and equivalents as of September 30, 2026. The company continues clinical development of apitegromab in additional indications and is advancing other pipeline candidates including SRK-439. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Scholar Rock has achieved FDA approval and initiated commercialization of ISEMBYLD, marking a key milestone in translating its proprietary platform into a marketed product. The company’s pipeline includes multiple clinical-stage candidates with potential to address unmet needs in SMA, FSHD, and other rare neuromuscular diseases. Development of a subcutaneous formulation of apitegromab may enhance patient convenience and broaden market reach. Ongoing regulatory submissions in Europe and Japan could expand geographic market access. The company’s strong liquidity supports continued investment in research, development, and commercialization capabilities.
Scholar Rock faces substantial clinical, regulatory, and commercial risks inherent to biopharmaceutical development. The company has incurred significant operating losses and an accumulated deficit, reflecting ongoing investment without material profitability. Regulatory approvals outside the U.S. remain pending, and clinical trial outcomes for pipeline candidates are uncertain. Commercial launch of ISEMBYLD is at an early stage with limited product revenue to date. Competition in neuromuscular disease therapies is intense, and the company’s ability to sustain operations depends on successful execution of development and commercialization strategies.
Scholar Rock’s moat derives from its proprietary platform targeting the TGFβ superfamily, enabling selective inhibition of latent growth factors implicated in muscle atrophy and other rare diseases. The company’s first-to-market FDA approval of ISEMBYLD as a muscle-targeted therapy for SMA patients receiving SMN2-targeted treatment establishes a unique commercial position. Its pipeline includes differentiated product candidates with novel mechanisms of action and ongoing clinical development in rare neuromuscular diseases. Intellectual property protection and specialized expertise in growth factor biology contribute to barriers to entry. However, the company operates in a highly competitive and regulated biopharmaceutical environment with significant clinical and regulatory risks.
• Clinical and Regulatory Risk: The success of Scholar Rock’s product candidates depends on favorable clinical trial results and regulatory approvals, which are uncertain and subject to delays or failures.
• Commercialization Risk: Early-stage commercial launch of ISEMBYLD involves uncertainties in market acceptance, reimbursement, and sales execution.
• Financial Risk: The company has a history of operating losses and an accumulated deficit, requiring continued capital to fund operations and development.
• Competitive Risk: Scholar Rock operates in a competitive landscape with other companies developing therapies for SMA and neuromuscular diseases.
• Operational Risk: Execution risks include manufacturing, supply chain, intellectual property protection, and scaling commercial infrastructure.
Business trends: Expansion of commercial sales of ISEMBYLD in the U.S. following FDA approval, ongoing clinical development in SMA and other neuromuscular diseases, and regulatory submissions in Europe and Japan.
Execution milestones: Completion and data release of Phase 1 trial for SRK-439, progress in Phase 2 trials for apitegromab in SMA and FSHD, and scaling of commercialization infrastructure.
Key risks: Clinical and regulatory uncertainties, early-stage commercialization challenges, financial sustainability amid operating losses, and competitive pressures in neuromuscular disease therapies.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Scholar Rock Holding Corp is a global biopharmaceutical company focused on spinal muscular atrophy (SMA) and other rare neuromuscular diseases [S2].
- The company has a proprietary platform targeting the transforming growth factor beta (TGFβ) superfamily to develop monoclonal antibodies that selectively inhibit precursor forms of growth factors [S2].
- Scholar Rock's approved product is ISEMBYLD™ (apitegromab-mstn), approved by the FDA on September 11, 2026, for treatment of SMA in patients two years and older receiving SMN2-targeted therapy [S2].
- The company initiated U.S. commercial launch of ISEMBYLD in Q3 2026 [S2].
- Scholar Rock resubmitted its Marketing Authorisation Application for apitegromab to the European Medicines Agency in October 2026 and submitted a Japanese New Drug Application in November 2026 [S2].
- Clinical development includes ongoing long-term extension ONYX trial and Phase 2 OPAL trial for SMA patients under two years, and Phase 2 FORGE trial for facioscapulohumeral muscular dystrophy (FSHD) initiated in Q2 2026 [S2].
- A subcutaneous formulation of apitegromab has completed Phase 1 with favorable bioavailability and pharmacodynamics; further regulatory engagements are planned [S2].
- SRK-439, a novel anti-pro/latent myostatin antibody, is in Phase 1 clinical trial with topline data expected by year-end 2026 [S2].
- The company is seeking partnerships for non-neuromuscular programs including SRK-181 (solid tumors), SRK-373 (fibrotic diseases), and SRK-256 (iron-restricted anemias) [S2].
- Scholar Rock reported net product revenue of $0.57 million from ISEMBYLD sales in Q3 2026, its first quarter of commercial sales [S2].
- For the quarter ended September 30, 2026, research and development expenses were $54.1 million, up 7.2% year-over-year, reflecting ongoing clinical and development activities [S2].
- Net loss for Q3 2026 was $107.2 million, compared to $102.2 million in Q3 2025 [S2].
- As of September 30, 2026, Scholar Rock had cash and equivalents of $366.3 million and short-term investments of $47.3 million, with a current ratio of 5.41 and cash ratio of 5.16, indicating strong liquidity [S2].
- The company has incurred significant operating losses since inception, with an accumulated deficit of $1.6 billion as of September 30, 2026 [S2].
- Scholar Rock's business model centers on developing and commercializing therapies targeting muscle atrophy via myostatin inhibition and related pathways [S2].
- The company faces risks typical of clinical-stage biopharmaceutical firms, including regulatory approvals, clinical trial outcomes, manufacturing, and commercialization challenges [S2].
- Recent news highlights include FDA approval of ISEMBYLD, resubmission of European filing for SMA therapy, and ongoing clinical trial progress [N1][N2][N3].
- Multiple analyst firms have maintained overweight or buy recommendations on Scholar Rock in late 2025 and early 2026 [N7][N8].
Generated 2026-11-10
- S1 | 2026-03-03 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-10-08 | www.nasdaq.com | Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval | https://www.nasdaq.com/articles/scholar-rock-revives-european-filing-sma-therapy-after-us-approval
- N2 | 2026-09-18 | www.nasdaq.com | Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead | https://www.nasdaq.com/articles/weekly-buzz-rare-bayry-win-approvals-sion-cuts-jobs-gsk-deals-azn-rhhby-lead
- N3 | 2026-08-13 | www.nasdaq.com | Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/scholar-rock-srrk-q2-2026-earnings-call-transcript
- N4 | 2026-08-07 | www.nasdaq.com | Scholar Rock Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/scholar-rock-q2-earnings-call-highlights
- N5 | 2026-05-09 | www.nasdaq.com | Scholar Rock Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/scholar-rock-q1-earnings-call-highlights
- N6 | 2026-03-02 | www.nasdaq.com | Pre-Market Earnings Report for March 3, 2026 : AZO, TGT, SE, VIK, ONON, BBY, THO, SRRK, SRAD, KTB, MRX, AMLX | https://www.nasdaq.com/articles/pre-market-earnings-report-march-3-2026-azo-tgt-se-vik-onon-bby-tho-srrk-srad-ktb-mrx-amlx
- N7 | 2025-12-18 | www.nasdaq.com | Barclays Maintains Scholar Rock Holding (SRRK) Overweight Recommendation | https://www.nasdaq.com/articles/barclays-maintains-scholar-rock-holding-srrk-overweight-recommendation-0
- N8 | 2025-11-19 | www.nasdaq.com | JP Morgan Maintains Scholar Rock Holding (SRRK) Overweight Recommendation | https://www.nasdaq.com/articles/jp-morgan-maintains-scholar-rock-holding-srrk-overweight-recommendation
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


